Sorafinib in kidney cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Escudier, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INTERFERON; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NONHUMAN; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SKIN MANIFESTATION; SKIN TOXICITY; TUMOR XENOGRAFT; ARTICLE; DRUG COMBINATION; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG THERAPY, COMBINATION; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 54349115688     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm301     Document Type: Conference Paper

References (16)

1. Marais R, Light Y, Paterson HF et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997; 272: 4378-4383.
2. Oka H, Chatani Y, Hoshino R et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55: 4182-4187.
3. Davies H, Bignall GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
4. Nagy A, Balint I, Kovacs G. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer 2003; 106: 980-981.
5. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
6. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-1861.
7. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-1694.
8. Strumberg D, Voliotis D, Moeller JG et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002; 40: 580-581.
9. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
10. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
11. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007; 356: 125-134.
12. Escudier B, Szczylik C, Demkow T et al. Phase II trial of sorafenib vs interferon in first-line patients with advanced renal cell carcinoma: results of period 1 and 2 after cross over. 5th International Symposium on Targeted Anticancer Therapies, 0203. Amsterdam 2007; March 8-10.
13. Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with interferon alpha-2a in patients with unresectable and/ or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007; 13: 1801-1809.
14. Lamuraglia M, Escudier B, Chami L et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42: 2472-2479.
15. Gollob J, Richmond T, Jones J et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-{alpha}2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4538.
16. Sosman JA, Flaherty K, Atkins MB et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol (Meeting Abstracts) 2006; 24: 3031.